 Thanks, Jen. It's a pleasure to be here. Let me first of all start off by expressing my appreciation to our two Agency colleagues NSF USDA for joining us to put this This workshop together. We had a very selfish reason why we wanted this workshop, which is what I'm going to talk about We're related to a round of strategic planning We're in the midst of but it was really great to be able to reach out to two other federal agencies who have overlapping interests in this area and having such a productive collaboration to put this on certainly appreciate people who organize this and Appreciate all of you for coming and now staying until through through Friday afternoon before departing I Unfortunately my schedule a little crazy this week and so I wasn't able to get here yesterday I watched a little bit on our video feed and I I've been hearing from various people including some of the staff that sounds like Extremely robust discussion and great presentation. So I appreciate all of you who have participated what I wanted to do is to Looking out at the audience and looking at the roster people are here There are a number of you who have not been involved in any of the activities so far to my knowledge Related to NHGRI's current round of strategic planning And so I was asked to come give a brief overview about this But also we wanted then I'll turn this over to Carolyn Hutter who will help along with I think Jen and others to help sort of Stimulate a discussion to get your feedback while we have a captive audience because this is an area We are interested in and knowing what your thoughts are as it integrates with a very important part of NHGRI's future Now one thing to appreciate about NHGRI maybe the whole field of genomics But certainly NHGRI is that we very much embrace the notion of strategic planning We'd probably do it in a be honest with you in a more robust fashion than any of the other 26 other institutes and centers at NIH. I think the history of that relates to our origins Where we were created as a part of NIH to lead The NIH's effort in the human genome project and we sort of just grew up As part of an international collaboration of the human genome project Which was guided by a series of strategic plans three of those are shown here whereby there was this very Comfortable feeling of engaging the community getting their input on how do you actually do what you're trying to achieve? But recognizing that within a year or two you're willing to rip that up and come up with a new approach as Technologies advance and new opportunities arise and we have just stuck to that kind of a style playbook to help frame Our scientific agenda when the genome project ended literally the day the genome project ended We published this strategic plan in 2003 which really guided us for the rest of that decade and then in 2011 We published our most recent strategic plan One that went beyond some of the fundamentals we had described at the end of the human genome project And up and through 2010 but in particular Expanded our research portfolio that included reaching out into clinical research and thinking about how to implement genomic medicine And so this 2011 strategic plan sort of is organized around five major Progressive research domains that start from the far left Understanding fundamentals of structure and function of genomes in the middle more translational work to use genomics to understand human disease Of course an important priority at the National Institutes of Health and then in the far and the right word domains Thinking about how you can use genomics to advance medicine eventually improve the effectiveness of health care And this is sort of the centerpiece figure from our 2011 strategic plan I can tell you we have almost every aspect of the Institute Organized around this strategic plan and it has served us well actually serves us extremely well even up to the present time But in thinking about it, it was you know Basically came out a strategic plan and that took place mostly in 2009 2010 was really Drafted into and mostly written in 2010 and then was published in 2011 And we just felt as we thought about the next decade that it was probably important Not to stay too fixed to a strategic plan that at that point would be 10 years old And we just thought it was important for us to start the new decade with a new strategic plan And so as a result of that and having done this multiple times We know we need a two-plus years to accomplish this if we're going to do it Well and engage and and recognize and we were going to have to engage even more stakeholders than ever Because our community has just grown and grown and grown especially as we've moved from very basic genomics into more Translational and clinical applications of genomics. So we really plan for this going back to 2017 And then in February 2018 we formally kicked off this new Rhonda strategic planning knowing it would take us two years Sometime in 2020 we would publish it. We looked across 2020 Send one won't be a nice time to publish a new strategic plan and we like odometer moments And so we happen to pick October of 2020 because conveniently that'll be the 30th anniversary of the launch of the human genome project Just seemed like a good time to publish it. We're gonna publish this in October It means we really have to submit the manuscript sometime over the summer We need to have a good draft for feedback to get lots of feedback from people by the spring And so basically we've had this interval of time to try to think about all those different ways to get the input We want to write a strategic plan and thinking about what we're gonna be the elements we would use We just reached into the toolkit. We've used in previous Rhonda strategic planning But also grab some newer approaches and those are just listed here We've now had I think this engagement this afternoon probably is getting near number 40 If you're gonna add up all the ways We've been gone to meetings or had workshops or had town halls or had special sessions or had webinars Etc. Etc. I think our number is approaching 40 and this is just emblematic of the kind of things We've been doing both here in Bethesda Actually across the country and actually we've even gone abroad and done at least one or a couple of these kinds of things as well And so all these things are going on we are past the halfway mark We're probably about there in the process you can see we are certainly getting Past the point where we're just hearing open-ended feedback and we're be we have certainly are now Very much into synthesize and what we're hearing. I think some of the things you're gonna hear We're gonna put up in front of you relate to some of the early synthesis as you can see We hope as we hone in on the spring of 2020 when we want to have a draft Paper available for comment But before I turn this over to Caroline, there are two other nuances. I think I've really I in many ways shaped Many aspects I guarantee you these nuances will shape the crafting of the actual strategic plan because The world is a different place now from our perspective with respect in genomics Then it was previously in a ways that I'll describe and so there's just two nuances I want to introduce you to that I think are important for you to know the first nuance which if you're not Geeky familiar with NIH You may not quite appreciate but it is important for me to remind you about this is That the NIH has 27 institutes and centers and they are very different in size is the thing to know So here's NHGRI and if proportional to the diameter of that circle That is the size of our budget relative to the other 26 And you could quickly appreciate that while we all believe that genomics is incredibly important and while genomics has this massive Intellectual footprint the National Human Genome Research Institute is a small Institute at NIH Relative to the other most others in fact we account for about 1.5 percent of the NIH budget So keep that in mind now once upon a time that was probably perfectly fine when genomics was young And we were synonymous with genomics, but that's the other nuance. I want to introduce you to is There has been a remarkable I think successful dissemination of genomics across all of NIH obviously across all of biology and all the life sciences But if we're just honing in on the National Institute to Health Genomics has been widely widely widely disseminated across the NIH We think this is successful. We think this is what we should be doing is getting others to be doing genomics We should be enabling it, but it really does put us in a very different place now than we've been in the past And let me give you real data so you can appreciate the scale at which the world has changed around us at NIH So if you actually just search NIH databases for all the money We've given out of the money we spend on campus on our intramural program And you look at keywords like human genome and you simply ask the question What is the percent of NIH awarded funds that carry a keyword like human genomic that comes from our Institute? And look at that over different periods of time I can tell you that during the human genome project was a very easy number to keep track of because it was nearly 100% was over 95% and even when the genome project ended and we published our 2003 strategic plan it was still an easy number to keep track of NHGRI was largely synonymous with genomics research at NIH But starting 16 years ago the world began to change around us because we were successful at getting other Institutes to do genomics in very productive ways so that by 2011 when our strategic plan came out We'd actually dipped below 50% although still we were with our one and a half percent of the NIH budget We were still accounting for about 50% of genomics research But that's just not the case anymore. In fact by the time our 2020 strategic plan comes out It is RS right now. We're at about 15 percent Accounting for 15 percent of genomics research We think by the time our plan comes out that number is going to be about 10% So NHGRI once upon a time synonymous with genomics at NIH Almost a hundred percent of county for genomics research is now down to only about a tenth of genomics research at NIH that trend has been remarkably Important we think it's the right trend But at the same time it changes our place in the universe as the way we think of it And in fact before we actually even embarked on our new round of strategic planning Recognizing that things were changing around us that we felt it was really important to sort of re-identify ourselves What is our role in NIH and biomedicine and so forth and we actually came up with the new mantra and probably you've seen some of This on slides and so forth, but our strategic plan in 2020 is very much going to be a reflection of our view of what it is like to be at the forefront of genomics We are not all of genomics We're not even 20% of at NIH only about 10% of genomics But we are the forefront of genomics and what we need to hear and what we're constantly asking is when you're at the Forefront of genomics, what does that mean because that's what we should be doing with the 10% of NIH money going to genomics research So in summary this strategic plan that you can look for in October of 2020 is going to be we think the driving force for much of Genomics at NIH and around the world. We hope it'll provide clear Yes, 2020 vision for using genomics to advance human health It's going to obviously guide our scientific priorities that will shape our research portfolio It will also foster partnerships that are much wider and further than we've ever had before because our Communities have gotten bigger especially as we've begun to touch health care and Make genomic medicine a reality such that now patients are part of our stakeholder group not to mention policy groups and other general public communities And of course what's going to be most important about the strategic plan is it's going to really help us define What does it mean to be at the forefront of genomics? So lots of ways to engage with us obviously websites and through email and through social media and so forth But that's the overview. I wanted to provide you and with that in mind I'm going to turn this over to Carolyn Hutter who I think is going to now drill down from this very high level that I Describe to what we would like to hear from you in the next I don't know 40 minutes or 30 minutes